The content on this site is intended for healthcare professionals only
Dr Besse and Dr Bhosle discuss and answer questions arising from debate on the merits or lack thereof of maintenance as a treatment strategy in NSCLC.
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Research highlights in lung cancer
Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
OncoAlert Round Up for August 4th - 10th, 2023
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
